Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02223598
Title A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies (CLC-102)
Acronym CLC-102
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Cleave Biosciences, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | CAN

Facility Status City State Zip Country Details
City of Hope National Medical Center Duarte California 91010 United States Details
University of California, San Francisco San Francisco California 94143 United States Details
Emory University Atlanta Georgia 30322 United States Details
RCCA MD Bethesda Maryland 20817 United States Details
Washington University Saint Louis Missouri 63110 United States Details
Hackensack University Medical Center Hackensack New Jersey 07601 United States Details
Princess Margaret Cancer Centre Toronto Ontario M5G 2M9 Canada Details
Cedars Cancer Centre, McGill University Health Centre Montreal Quebec H4A 3J1 Canada Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field